Kyowa Hakko Kirin Co., Ltd., was inaugurated in October 2008 as an R&D-based company with special strengths in biotechnology, following the integration of Kirin Pharma Company, Limited, of the Kirin Group, and Kyowa Hakko Co., Ltd. The Company is dedicated to the creation of new value in the life sciences, especially in its core business segments of Pharmaceuticals and Bio-Chemicals, and strives to contribute to the health and well-being of people around the world. We are seeking new heights by aggressively promoting our proprietary technologies in each business domain.

In Pharmaceuticals operations, the Company has actively engaged in the R&D, production, and sale of pharmaceuticals that address medical needs in such areas as renal anemia, cancer, allergies, and hypertension. Utilizing leading-edge biotechnologies, particularly antibody technologies, we are aiming to be a global specialty pharmaceutical company that creates innovative pharmaceuticals.

Bio-Chemicals operations are centered on Kyowa Hakko Bio Co., Ltd., which was established as a separate company at the same time as the inauguration of Kyowa Hakko Kirin and is a global leader in fermented bulk products, such as amino acids, nucleic acids, and related compounds.

In Chemicals operations, the Company is expanding lineups of specialty chemicals that contribute to environmental conservation.